Home › Funds › RA CAPITAL MANAGEMENT, L.P. › MLYS

RA CAPITAL MANAGEMENT, L.P. position in MLYS

MINERALYS THERAPEUTICS INC · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 7,692,750 shares of MLYS (MINERALYS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$207.6M, representing 1.80% of its reported portfolio and ranking #12 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed MLYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)7.69M sh
Reported value held$207.55M
Portfolio Weight1.80%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s MLYS position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in MLYS in Q3 2023 at 3,178,476 shares (US$30.2M). The position peaked in Q3 2025 at 7,323,750 shares, worth US$277.7M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 7,692,750 shares valued at US$207.6M. Notable position changes include a 53% increase in Q1 2024 (shares fell 9% over the following quarter), a 27% increase in Q1 2025 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.18M $30.23M New
Q4 2023 3.18M $27.33M Hold
Q1 2024 4.85M $62.63M Add
Q2 2024 4.85M $56.76M Hold
Q3 2024 4.85M $58.75M Hold
Q4 2024 4.85M $59.72M Hold
Q1 2025 6.15M $97.62M Add
Q2 2025 6.15M $83.17M Hold
Q3 2025 7.32M $277.72M Add
Q4 2025 7.32M $265.78M Hold
Q1 2026 7.69M $208.40M Add
Q2 2026 7.69M $207.55M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MLYS and 13F data

MLYS (MINERALYS THERAPEUTICS INC) is a Health Care company. 53 other funds we track also report a position in MLYS — the largest reported positions include Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$106.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MLYS

All MLYS fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held MLYS?

RA CAPITAL MANAGEMENT, L.P. has disclosed MLYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in MLYS?

As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 7.69M shares of MLYS (MINERALYS THERAPEUTICS INC), valued at $207.55M, representing 1.80% of its reported portfolio and ranking #12.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling MLYS?

In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in MLYS. The position peaked in Q3 2025 at 7.32M shares.

Which other funds hold MLYS?

Other major institutional holders of MLYS include Catalys Pacific, LLC, Samsara BioCapital, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.